Physician profile
Nathaniel D Rapp
NPI 1043442841
$3,071.73
in general payments reported to CMS, 2019-2025
26 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $210 · 2021: $980 · 2022: $541 · 2023: $533 · 2024: $266 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.95 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,162.29 | 2019-2023 | |
| Daiichi Sankyo INC. | $463.69 | 2019-2023 | Injectafer |
| Organon LLC | $175.99 | 2021-2025 | Nexplanon |
| Astellas Pharma US INC | $165.00 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $164.32 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $92.52 | 2021-2025 | |
| Pfizer INC. | $91.84 | 2023-2025 | |
| Hologic Sales and Service, LLC | $86.99 | 2024 | Myosure Tissue Removal Device, Thinprep 2000 Processor, Aptima |
| Agile Therapeutics, INC. | $75.28 | 2021-2023 | Twirla |
| Sumitomo Pharma America, INC. | $72.28 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $69.46 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $68.60 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $56.50 | 2021 | |
| Medtronic, INC. | $50.88 | 2021-2024 | Ligasure, Truclear |
| Minerva Surgical, INC | $47.74 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $42.34 | 2019-2020 | |
| Roche Diagnostics Corporation | $29.06 | 2019 | |
| Axonics, INC. | $20.47 | 2024 | Bulkamid |
| Myovant Sciences INC. | $20.24 | 2022 | |
| Meditrina | $19.88 | 2025 | |
| Allergan, INC. | $19.32 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $18.38 | 2023 | Seglentis |
| Millicent US INC | $17.79 | 2025 | Intrarosa, Femring |
| Amag Pharmaceuticals, INC. | $14.33 | 2019 | |
| Exeltis, USA INC. | $13.84 | 2020 | |
| Acessa Health INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Rapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.